Publications by Professor Ruth Plummer - ePrints

Browsing publications by Professor Ruth Plummer.

Newcastle Authors	Title	Year
Professor Ruth Plummer	A three-arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanoma	2024
Professor Alastair Greystoke Professor Ruth Plummer Dr Christoph Oing Dr Pasquale Rescigno	Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer: A Quantitative Synthesis and Meta-analysis	2024
Dr Victoria Coyle Professor Ruth Plummer	Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis: the EASI-SWITCH RCT	2024
Dr Abi Gault Dr Linda Hogarth Dr Kristian Williams Professor Alastair Greystoke Professor Neil Rajan et al.	Monitoring immunE DysregulAtion foLLowing Immune checkpOint-inhibitioN (MEDALLION): protocol for an observational cancer immunotherapy cohort study	2024
Professor Ruth Plummer	Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial	2024
Dr Yvette Drew Professor Ruth Plummer	Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study	2024
Sarah Rae Ellie Taylor Joseph Hoben Dr Christoph Oing Professor Alastair Greystoke et al.	Social determinants of health inequalities in early phase clinical trials in Northern England	2024
Julieann Sludden Professor Gareth Veal Professor Ruth Plummer	A Phase 1/2A trial of idroxioleic acid: First-in-class sphingolipid regulator and glioma cell autophagy inducer with antitumor activity in refractory glioma	2023
Professor Gareth Veal Professor Steve Wedge Dr Christopher Bacon Professor Philip Sloan Professor Alastair Greystoke et al.	A phase I dose-escalation study of AZD3965, an oral monocarboxylate transporter 1 inhibitor, in patients with advanced cancer	2023
Dr Fadhel Shaheen Professor Ruth Plummer	Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: a multicenter, retrospective cohort study	2023
Professor Ruth Plummer	Early switch to oral antibiotic therapy in patients with low-risk neutropenic sepsis (EASI-SWITCH): a randomized non-inferiority trial	2023
Dr Kristian Williams Abigail Gault Dr Amy Anderson Professor Christopher Stewart Professor Chris Lamb et al.	Immune-related adverse events in checkpoint blockade: Observations from human tissue and therapeutic considerations	2023
Professor Ruth Plummer	Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma	2023
Sarah Rae Dr Linda Hogarth Alison Bridgewood Lisa Brown-Schofield Dr Saira Bashir et al.	Prevalence of mutations in common tumour types in Northern England and comparable utility of national and international Trial Finders	2023
Jing Lim Grace Mallett Dr David McDonald Dr Gill Hulme Dr Stephanie Laba et al.	Programmed cell death-1 receptor-mediated regulation of Tbet⁺NK1.1^- innate lymphoid cells within the tumor microenvironment	2023
Professor Ruth Plummer	A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer	2022
Professor Ruth Plummer	Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer	2022
Dr Jingky Lozano-Kuehne Dr Nicola Cresti Professor Ruth Plummer	Results of the Phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer	2022
Dr Tobias Menne Professor Julie Irving Professor Ruth Plummer Dr Geoff Shenton Professor Gareth Veal et al.	Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trial	2022
Professor Ruth Plummer	Introduction to the National Cancer Imaging Translational Accelerator (NCITA): a UK-wide infrastructure for multicentre clinical translation of cancer imaging biomarkers	2021
Professor Ruth Plummer	Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours	2021
Dr Helen Marshall Professor Ruth Plummer Dr Gurdeep Sagoo	The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma	2021
Dr Christopher Bacon Dr George Petrides Dr Nicola Leech Dr Fiona Jenkinson Professor Ruth Plummer et al.	A case of malignant hyperlactaemic acidosis appearing on treatment with the mono-carboxylase transporter 1 inhibitor AZD3965.	2020
Professor Ruth Plummer	Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis (the EASI-SWITCH trial): study protocol for a randomised controlled trial	2020
Professor Ruth Plummer	Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma	2020
Dr Nicola Cresti Professor Ruth Plummer	A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine	2019
Professor Ruth Plummer Professor Alastair Greystoke	A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours	2019
Professor Ruth Plummer	Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: Phase 1b results from the JAVELIN Solid Tumor trial	2019
Dr Simon Findlay Dr Jason Gill Professor Ruth Plummer Carol De Santis Dr Chris Plummer et al.	Chronic cardiovascular toxicity in the older oncology patient population	2019
Dr Stamatina Verykiou Michael Alexander Dr Noel Edwards Professor Ruth Plummer Dr Bill Chaudhry et al.	Harnessing autophagy to overcome MEK-inhibitor induced resistance in metastatic melanoma	2019
Professor Ruth Plummer	Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF^V600E or BRAF^V600Kmutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial	2019
Professor Ruth Plummer Professor Steve Wedge Professor Gareth Veal	A first-in-human first-in-class (FIC) trial of the monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 in patients with advanced solid tumours	2018
Dr Sarah Fordham Dr Helen Blair Dr Claire Elstob Professor Ruth Plummer Dr Yvette Drew et al.	Inhibition of ATR acutely sensitises acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase	2018
Dr Marina Danilenko Elaine Stamp Dr Deborah Stocken Monique Zangarini Amy Cranston et al.	Targeting tropomyosin receptor kinase in cutaneous CYLD defective tumors (TRAC): A randomised placebo-controlled early phase trial with pegcantratinib	2018
Professor Ruth Plummer	A Phase II Multicentre, Open-Label, Proof-of-Concept Study of Tasquinimod in Hepatocellular, Ovarian, Renal Cell, and Gastric Cancers	2017
Professor Ruth Plummer	Adjuvant Dabrafenib plus Trametinib in stage III BRAF-mutated melanoma	2017
Professor Alastair Greystoke Dr Noor MD Haris Professor Ruth Plummer	SELECT-3: A phase i study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting	2017
Amy Cranston Dr Deborah Stocken Elaine Stamp Professor Ruth Plummer Professor Sir John Burn et al.	Tropomyosin Receptor Antagonism in Cylindromatosis (TRAC), an early phase trial of a topical tropomyosin kinase inhibitor as a treatment for inherited CYLD defective skin tumours: study protocol for a randomised controlled trial.	2017
Professor Neil Rajan Dr Thomas Oliphant Professor Ruth Plummer Dr James Langtry	Advanced basal cell carcinomas treated by vismodegib and Mohs micrographic surgery: does neoadjuvant treatment have a role?	2016
Professor Ruth Plummer Professor Steve Wedge	Clinical development of new drug-radiotherapy combinations	2016
Dr Rachel Pearson Professor Peter Thelwall Jim Snell Dr Piotr Pieniazek Professor Rakesh Heer et al.	Evaluation of early response to neoadjuvant chemotherapy in muscle-invasive bladder cancer using dynamic contrast-enhanced MRI and diffusion weighted MRI: MARBLE study	2016
Dr Rachel Pearson Professor Peter Thelwall Jim Snell Dr Piotr Pieniazek Professor Rakesh Heer et al.	Evaluation of early responses to neoadjuvant chemotherapy in muscle-invasive bladder cancer using a dynamic contrast-enhanced MRI and diffusion-weighted MRI: MARBLE study	2016
Barry Dent Laura Ogle Dr Rachel O'Donnell Dr Ujjal Mallick Professor Nicola Curtin et al.	High-resolution imaging for the detection and characterisation of circulating tumour cells from patients with oesophageal, hepatocellular, thyroid and ovarian cancers	2016
Laura Ogle Dr James Orr Dr Catherine Willoughby Dr Claire Hutton Professor Stuart McPherson et al.	Imagestream detection and characterisation of circulating tumour cells - a liquid biopsy for hepatocellular carcinoma?	2016
Professor Ruth Plummer	Investigator-assessed efficacy and safety of sonidegib in patients with locally advanced basal cell carcinoma and metastatic basal cell carcinoma: results of the BOLT 30-month analysis	2016
Dr Peter Stephens Professor Ruth Plummer Professor Nicola Curtin	mTORC1 and DNA-PKcs as novel molecular determinants of sensitivity to Chk1 inhibition	2016
Dr Yvette Drew Dr Martin Highley Julieann Sludden Dr James Murray Dr David Jamieson et al.	Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly (ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer	2016
Professor Ruth Plummer Professor Alastair Greystoke	SELECT-3: A phase I study of selumetinib in combination with platinum doublet chemotherapy for advanced NSCLC in the first-line setting	2016
Professor Ruth Plummer	Sonidegib safety in patients with locally advanced Basal Cell Carcinoma and efficacy based on tumor aggressiveness	2016
Professor Ruth Plummer	The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma	2016
Ashleigh McConnell Dr Robert Ellis Professor Ruth Plummer Professor Penny Lovat Dr Graeme O'Boyle et al.	The prognostic significance and impact of the CXCR4-CXCR7-CXCL12 axis in primary cutaneous melanoma	2016
Dr Yvette Drew Professor Alastair Greystoke Professor Ruth Plummer	A first-in-human dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of oral 2-hydroxyoleic acid (2-OHOA) in adult patients (pt) with advanced solid tumors including grade III/IV glioblastoma multiforme (GBM).	2015
Dr Manolo D'Arcangelo Professor Ruth Plummer	A first-in-human study of intravenous BAL101553, a novel microtobule inhibitor, in patients with advanced solid tumors	2015
Professor Ruth Plummer	A Multicenter Phase I Study of Pazopanib in Combination with Paclitaxel in First-Line Treatment of Patients with Advanced Solid Tumors	2015
Professor Ruth Plummer Professor Alastair Greystoke	A phase Ib dose-escalation study of GSK2256098 (FAKi) plus trametinib (MEKi) in patients with selected advanced solid tumors	2015
Professor Ruth Plummer Ian Daniels	An adjuvant clinical trial of SCIB1, a DNA vaccine that targets dendritic cells in vivo, in fully resected melanoma patients	2015
Dr Stamatina Verykiou Professor Ruth Plummer Professor Penny Lovat	Contribution of autophagy to the survival of melanoma-initiating CD271-positive subpopulations	2015
Professor Ruth Plummer Dr Jane Margetts Professor John Lunec Dr Joyce Nutt	Phase I Study of Lapatinib and Pemetrexed in the Second-Line Treatment of Advanced or Metastatic Non-Small-Cell Lung Cancer With Assessment of Circulating Cell Free Thymidylate Synthase RNA as a Potential Biomarker	2015
Professor Ruth Plummer	Phase I study of two dosing schedules of the investigational oral pan-RAF kinase inhibitor MLN2480 in patients (pts) with advanced solid tumors or melanoma	2015
Professor Ruth Plummer	Phase I Study to Assess the Combination of Afatinib with Trastuzumab in Patients with Advanced or Metastatic HER2-Positive Breast Cancer	2015
Professor Ruth Plummer	Pivotal role of sphingomyelin synthase (SGMS) expression and activity in glioma patient survival presents a potential therapeutic target	2015
Professor Ruth Plummer	Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma	2015
Professor Ruth Plummer	Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial	2015
Professor Ruth Plummer	Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial	2015
Barry Dent Dr Rachel O'Donnell Laura Ogle Padmini Ramesh Nick Hayes et al.	Detection and characterization of circulating tumor cells by imaging flow cytometry	2014
Dr Laura Ogle Dr David Jamieson Dr Rachel O'Donnell Barry Dent Professor Nicola Curtin et al.	Detection of circulating tumour cells (CTCS) in hepatocellular (HCC) cancer patients using the ImageStream^x	2014
Professor Ruth Plummer	DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma	2014
Professor Ruth Plummer	Dose-Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study	2014
Professor Alan Calvert Professor Ruth Plummer	Effect of erlotinib on CYP3A activity, evaluated in vitro and by dual probes in patients with cancer	2014
Professor Ruth Plummer	First-in-human phase 1 study of MLN2480, an investigational oral pan-RAF kinase inhibitor, in patients (pts) with relapsed or refractory solid tumors, including BRAF/NRAS-mutant melanoma	2014
Professor Ruth Plummer	Interim analysis of STEVIE, a single-arm, open-label, multicentre study to evaluate the safety of the hedgehog pathway inhibitor vismodegib in patients with advanced basal cell carcinoma	2014
Professor Neil Rajan Dr Piotr Pieniazek Paul Hainsworth Dr Fiona Douglas Professor Ruth Plummer et al.	Mesenteric cysts in Gorlin syndrome: a mimic of metastatic disease	2014
Professor Ruth Plummer	Outcome of patients with sarcoma and other mesenchymal tumours participating in phase I trials: a subset analysis of a European Phase I database	2014
Professor Ruth Plummer Dr Nicola Cresti Dr Yvette Drew Dr Peter Stephens Dr Jared Thornton et al.	Phase 1 study of the PARP inhibitor E7449 as a single agent in patients with advanced solid tumors or B-cell lymphoma	2014
Professor Ruth Plummer Ian Daniels	Phase I trial of ImmunoBody in melanoma patients	2014
Professor Ruth Plummer	Poly(ADP-ribose)polymerase (PARP) Inhibitors: From Bench to Bedside	2014
Ashleigh McConnell Dr Robert Ellis Dr Graeme O'Boyle Professor Ruth Plummer Dr Stamatina Verykiou et al.	Prognostic significance of CXCR4 expression in cutaneous melanoma	2014
Professor Ruth Plummer	The HALO study: A phase I-II of the oral HSP90 inhibitor Debio0932 in combination with SOC in first- and second-line therapy of advanced NSCLC	2014
James Murray Huw Thomas Philip Berry Suzanne Kyle Dr Miranda Patterson et al.	Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules	2014
Dr Yvette Drew Ajay Gupta Professor Ruth Plummer	A Phase 1 Study of Oral or Intravenous Rucaparib in Combination in Combination with Platinum-Containing Chemotherapeutic Regimens: Analysis of Patients with Ovarian or Peritoneal Tumors	2013
Dr Nicola Cresti Professor Ruth Plummer	A phase 1 study of oral rucaparib in combination with carboplatin	2013
Dr Nicola Cresti Dr Yvette Drew Professor Ruth Plummer	A phase I study of oral rucaparib in combination with carboplatin	2013
Professor Ruth Plummer	A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors	2013
Professor Ruth Plummer Dr Evan Mulligan Professor Nicola Curtin Professor Alan Calvert	A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation	2013
Professor Ruth Plummer	DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma	2013
Dr Jane Margetts Dr Yvette Drew Dr Peter Stephens Professor Alan Calvert Professor Ruth Plummer et al.	Erratum to: Phase I study of PM00104 (Zalypsis (R)) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors (vol 31, pg 623, 2013 Doi: 10.1007/s10637-012-9843-5)	2013
Dr Graeme O'Boyle Isabella Swidenbank Dr Helen Marshall Catriona Barker Dr Jane Renwick et al.	Inhibition of CXCR4-CXCL12 chemotaxis in melanoma by AMD11070	2013
Professor Ruth Plummer	Inhibitor of ATR (Ataxia Telangiectasia and RAD3 Related) Kinase	2013
Professor Ruth Plummer	Interim analysis of STEVIE, a single-arm, open-label, multicentre study to evaluate the safety of the hedgehog pathway inhibitor vismodegib in patients with advanced basal cell carcinoma	2013
Professor Ruth Plummer	Ipilimumab in the real world: The UK expanded access programme (EAP) experience in advanced melanoma	2013
Dr Jane Margetts Dr Yvette Drew Professor Ruth Plummer	Phase I study of PM00104 (Zalypsis (R)) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors	2013
Professor Ruth Plummer	Phase II study of danusertib (D) in advanced/metastatic non-small cell lung cancers (NSCLC)	2013
Professor Ruth Plummer Professor Alan Calvert	Phase I-II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma	2013
Professor Ruth Plummer	Vemurafenib for the Treatment of Locally Advanced or Metastatic BRAF V600 Mutation-Positive Malignant Melanoma: A NICE Single Technology Appraisal	2013
Dr Ahmed Elattar Dr Asima Mukhopadhyay Dr Fadhel Shaheen Professor Ruth Plummer Professor Craig Robson et al.	Androgen receptor expression is a biological marker for androgen sensitivity in high grade serous epithelial ovarian cancer	2012
Dr Asima Mukhopadhyay Professor Ruth Plummer Dr Ahmed Elattar Dr San Soo Hoo Bisha Uzir et al.	Clinicopathological features of homologous recombination deficient epithelial ovarian cancers: Sensitivity to PARP inhibitors, platinum and survival	2012
Dr Asima Mukhopadhyay Professor Ruth Plummer Dr Ahmed Elattar Dr San Soo Hoo Bisha Uzir et al.	Clinicopathological features of homologous recombination deficient epithelial ovarian cancers: Sensitivity to PARP inhibitors, platinum and survival	2012
Dr Asima Mukhopadhyay Professor Ruth Plummer Dr Ahmed Elattar Dr San Soo Hoo Bisha Uzir et al.	Clinicopathological Features of Homologous Recombination-Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival	2012
Dr Aiste McCormick Dr Asima Mukhopadhyay Professor Ruth Plummer Professor Nicola Curtin Professor Richard Edmondson et al.	Defective homologous recombination in human cancers	2012
Dr Britta Vormoor Sarah Wilkinson Fiona Harvey Professor Ruth Plummer Professor Nicola Curtin et al.	Ewing's Sarcoma Cells Can Be Sensitized to Temozolomide and to a Lesser Extent to Radiotherapy by Co-treatment with a PARP-inhibitor (AG014699)	2012
Professor Ruth Plummer	Imaging vascular function for early stage clinical trials using dynamic contrast-enhanced magnetic resonance imaging	2012
Professor Ruth Plummer	Ipilimumab for advanced melanoma in an expanded access programme (EAP): Ocular, mucosal and acral subtype UK experience	2012
Professor Ruth Plummer	Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy	2012
Professor Ruth Plummer	Patient Selection for Oncology Phase I Trials: A Multi-Institutional Study of Prognostic Factors	2012
Dr Nicola Cresti Professor Ruth Plummer	Pharmacokinetics of eribulin mesilate in combination with capecitabine in patients with advanced/metastatic cancer: Results from a phase IB dose-escalation study	2012
Professor Ruth Plummer	Phase Ib dose-escalation study of eribulin in combination with capecitabine in patients with advanced/metastatic cancer	2012
Professor Ruth Plummer	Understanding failure of PARP inhibition in the clinic	2012
Professor Ruth Plummer Professor Alan Boddy Julieann Sludden	A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours	2011
Professor Ruth Plummer Professor Hilary Calvert	A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors	2011
Professor Ruth Plummer	Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers	2011
Dr Asima Mukhopadhyay Professor Nicola Curtin Professor Ruth Plummer Professor Richard Edmondson	PARP Inhibitors And Epithelial Ovarian Cancer: An Approach To Targeted Chemotherapy And Personalized Medicine	2011
Professor Ruth Plummer Professor Alan Calvert	Phase I study of weekly plitidepsin as 1-hour infusion combined with carboplatin in patients with advanced solid tumors or lymphomas	2011
Professor Ruth Plummer	Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer?	2011
Professor Ruth Plummer	Poly(ADP-ribose) polymerase inhibitor development: are we in the right direction?	2011
Tomasz Zaremba Huw Thomas Mike Cole Dr Sally Coulthard Professor Ruth Plummer et al.	Poly(ADP-ribose) polymerase-1 (PARP-1) pharmacogenetics, activity and expression analysis in cancer patients and healthy volunteers	2011
Professor Ruth Plummer	Targeting DNA damage repair beyond PARP - further drugs or targets in development	2011
Dr Fadhel Shaheen Pawel Znojek Dr Ann Fisher Professor Ruth Plummer Dr Luke Gaughan et al.	Targeting the DNA Double Strand Break Repair Machinery in Prostate Cancer	2011
Dr Yvette Drew Dr Evan Mulligan Wan Vong Huw Thomas Suzanne Kyle et al.	Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA2	2011
Rachel Daniel Dr Agata Rozanska Dr Evan Mulligan Dr Yvette Drew Huw Thomas et al.	Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699	2010
Professor Ruth Plummer	Clinical Efficacy of the Anti-Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) Monoclonal Antibody Ipilimumab in Pretreated Metastatic Uveal Melanoma Patients [abstract]	2010
Tomasz Zaremba Huw Thomas Mike Cole Professor Ruth Plummer Professor Nicola Curtin et al.	Doxorubicin-induced suppression of poly(ADP-ribose) polymerase-1 (PARP-1) activity and expression and its implication for PARP inhibitors in clinical trials	2010
Professor Ruth Plummer	Educational Lecture: Mechanisms of DNA damage and repair	2010
Professor Ruth Plummer	Encouraging first experiences with PARP inhibitors	2010
Dr Joyce Nutt Kieran O'Toole Dr Fiona Black Mike Cole Professor Ruth Plummer et al.	Expression of methylthioadenosine phosphorylase (MTAP) in malignant pleural mesothelioma (MPM) and its implication for pemetrexed-based chemotherapy	2010
Dr Fathi Azribi Dr Nicholas Bown Dr Petra Dildey Stephen Clark Professor Ruth Plummer et al.	Extraosseous Pericardial Ewing's Sarcoma	2010
Professor Ruth Plummer	Perspective on the Pipeline of Drugs Being Developed with Modulation of DNA Damage as a Target	2010
Dr Peter Stephens Professor Alan Calvert Professor Ruth Plummer	Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors	2010
Professor Ruth Plummer	Radiotherapy Research Priorities for the UK	2010
Professor Alan Calvert Professor Ruth Plummer	Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours	2010
Dr Yvette Drew Professor Ruth Plummer	The emerging potential of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer	2010
Dr Joyce Nutt Kieran O'Toole Dr Fiona Black Amy Quinn Professor Alan Calvert et al.	The role of folate receptor alpha (FR alpha) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy	2010
Dr Agata Rozanska Dr Evan Mulligan Huw Thomas Deborah Castelbuono Professor Deborah Tweddle et al.	[abstract] Central nervous system (CNS) penetration, poly-ADP ribose polymerase (PARP) inhibition and enhancement of temozolomide activity against childhood medulloblastoma by AG-014699	2009
Dr Evan Mulligan Tomasz Zaremba Dr Yvette Drew Professor Ruth Plummer Professor Nicola Curtin et al.	[abstract] Validated sensitive immunological determination of PARP-1 protein levels and activity in cultured cells and human lymphocytes	2009
Dr Evan Mulligan Professor Nicola Curtin Professor Ruth Plummer	Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines	2009
Dr Joyce Nutt Kieran O'Toole Dr Fiona Black Professor Ruth Plummer Professor Alan Calvert et al.	Expression of folate receptor alpha (FRa) in malignant pleural mesothelioma patients by immunohistochemistry: a clinico-pathological analysis	2009
Dr Agata Rozanska Huw Thomas Dr Evan Mulligan Dr Yvette Drew Deborah Castelbuono et al.	Inhibition of Poly (ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma	2009
Professor Ruth Plummer	Ipilimumab in pretreated metastatic uveal melanoma patients: safety and clinical efficacy	2009
Professor Ruth Plummer	Ipilimumab in pretreated metastatic uveal melanoma patients: safety and clinical efficacy	2009
Professor Ruth Plummer	Ipilmumab in pretreated metastatic uveal melanoma patients: Safety and clinical efficacy	2009
Dr Yvette Drew Professor Ruth Plummer	PARP inhibitors in cancer therapy: Two modes of attack on the cancer cell widening the clinical applications	2009
Professor Ruth Plummer Melanie Griffin Dr Sally Coulthard Julieann Sludden Professor Alan Calvert et al.	Phase I Study of MG98, an Oligonucleotide Antisense Inhibitor of Human DNA Methyltransferase 1, Given as a 7-Day Infusion in Patients with Advanced Solid Tumors	2009
Professor Ruth Plummer	Plitidepsin alone or with dacarbazine (DTIC) as first-line treatment for advanced unresectable melanoma (AUM)	2009
Tomasz Zaremba Professor Ruth Plummer Dr Sally Coulthard Mike Cole Professor Nicola Curtin et al.	Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in a panel of human tumor cell lines [abstract]	2009
Tomasz Zaremba Mike Cole Dr Sally Coulthard Professor Ruth Plummer Professor Nicola Curtin et al.	Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines	2009
Professor Ruth Plummer Professor Alan Boddy Melanie Griffin Dr Mark Verrill	A phase I and pharmacokinetic study of lxabepilone in combination with carboplatin in patients with advanced solid malignancies	2008
Professor Ruth Plummer	CYP-activated prodrugs as chemotherapeutics	2008
Dr Yvette Drew Suzanne Kyle Professor Richard Edmondson Professor Ruth Plummer Professor Nicola Curtin et al.	Investigating DNA double strand break formation and repair in response to the PARP inhibitor AG014699 in cell lines defective in Homologous Recombination: a role for PARP inhibitors in sporadic cancers? [abstract]	2008
Professor Ruth Plummer Professor Alan Calvert	Mechanisms of chemoresistance to alkylating agents in malignant glioma.	2008
Professor Ruth Plummer Professor Alan Calvert	Open-label, non-randomised, inter-individual dose escalation of ZK 304709 with the evaluation of safety, tolerability, pharmacokinetics, oral bioavailability and orientating efficacy after daily administration in patients with advanced cancer (7 d treatment and 14 d recovery)	2008
Dr Christopher Jones Professor Ruth Plummer	PARP inhibitors and cancer therapy - early results and potential applications	2008
Professor Alan Calvert Professor Ruth Plummer Professor Nicola Curtin Professor Richard Edmondson Dr Yvette Drew et al.	PARP inhibitors in cancer treatment	2008
Professor Alan Calvert Professor Nicola Curtin Professor Ruth Plummer	PARP inhibitors in ovarian cancer	2008
Professor Ruth Plummer	Phase I and II clinical trials of the potent intravenous PARP inhibitor, AG014699	2008
Professor Ruth Plummer Professor Alan Calvert	Phase I study of the novel anti-cancer drug PM00104 as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors or lymphoma	2008
Professor Ruth Plummer Dr Christopher Jones Professor Nicola Curtin Professor Alan Boddy Professor Herbie Newell et al.	Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors	2008
Tomasz Zaremba Mike Cole Dr Sally Coulthard Professor Ruth Plummer Professor Nicola Curtin et al.	Poly(ADP-ribose) polymerase-1 (PARP-1) genomics in relation to activity in healthy volunteers and cancer patients	2008
Professor Alan Calvert Professor Ruth Plummer	The Development of Phase I Cancer Trial Methodologies: the Use of Pharmacokinetic and Pharmacodynamic End Points Sets the Scene for Phase 0 Cancer Clinical Trials	2008
Professor Ruth Plummer Professor Alan Calvert	[Meeting Abstract] A phase 1b study to assess the safety of lexatumumab, a human monoclonal antibody that activates TRAIL-R2, in combination with gemcitabine, pemetrexed, doxorubicin or FOLFIRI	2007
Professor Ruth Plummer Rebecca Perrett Professor Alan Calvert	A phase I and pharmacokinetic (PK) study of BIBW 2992, an oral irreversible dual EGFR/HER2 inhibitor	2007
Professor Alan Calvert Dr Fathi Azribi Rebecca Perrett Professor Ruth Plummer	Activity of BIBW2992, an oral irreversible dual EGFR/HER2 inhibitor, in non-small cell lung cancer (NSCLC) with mutated EGFR	2007
Professor Ruth Plummer Dr Louise Li Rebecca Perrett Professor Alan Calvert	Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers	2007
Professor Ruth Plummer Professor Alan Calvert	Targeting poly(ADP-ribose) polymerase: A two-armed strategy for cancer therapy	2007
Professor Ruth Plummer Rebecca Perrett Professor Alan Calvert	A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in patients with advanced solid tumours	2006
Professor Ruth Plummer Professor Alan Calvert	First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AGO14699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM)	2006
Professor Ruth Plummer	Inhibition of poly(ADP-ribose) polymerase in cancer	2006
Professor Ruth Plummer	Phase I dose-escalation study of novel oral multi-target tumor growth inhibitor (MTGI) ZK 304709 administered daily for 7 days of a 21-day cycle to patients with advanced solid tumors	2006
Professor Ruth Plummer Dr Louise Li Rebecca Perrett Professor Alan Calvert	Phase I study of BIBW2992, an oral irreversible dual EGFR/HER2 inhibitor, showing activity in tumours with mutated EGFR	2006
Professor Ruth Plummer Professor Alan Calvert	Phase I study of ispinesib in combination with carboplatin in patients with advanced solid tumors	2006
Professor Ruth Plummer	Poly(ADP-ribose) polymerase inhibition and its potential use in malignant melanoma	2006
Professor Ruth Plummer	Poly(ADPribose)polymerase inhibitors - the current clinical status	2006
Professor Ruth Plummer Rebecca Perrett Professor Alan Calvert	A phase 1 dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a continuous schedule in patients with advanced solid tumors	2005
Mark Leslie Julieann Sludden Professor Ruth Plummer Professor Alastair Greystoke Professor Alan Calvert et al.	A phase I and pharmacodynamic study of a 7 day infusion schedule of the DNMT1 antisense compound MG98.	2005
Professor Alan Boddy Professor Ruth Plummer Julieann Sludden Melanie Griffin Dr Mark Verrill et al.	A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules	2005
Professor Ruth Plummer Professor Alan Boddy Professor Nicola Curtin Professor Herbie Newell Lynsey Robson et al.	Final clinical, pharmacokinetic and pharmacodynamic results of the phase I study of the novel poly(ADP-ribose)polymerase (PARP) inhibitor, AG014699, in combination with temozolomide	2005
Professor Ruth Plummer Dr Christopher Jones Lynsey Robson Professor Alan Calvert	First in human phase I trial of the PARP inhibitor AG-014699 with temozolomide (TMZ) in patients (pts) with advanced solid tumors	2005
Professor Ruth Plummer Professor Alan Calvert	Phase I and pharmacokinetic study of HGS-ETR2, a fully human agonistic monoclonal antibody to TRAIL-R2, in patients with advanced solid malignancies	2005
Dr Ashraf Azzabi Dr Andrew Hughes Dr Paula Calvert Professor Ruth Plummer Melanie Griffin et al.	Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations	2005
Professor Ruth Plummer Dr Christopher Jones Professor Alan Boddy Professor Alan Calvert Professor Herbie Newell et al.	Temozolomide pharmacodynamics in patients with metastatic melanoma: DNA damage and activity of repair enzymes O⁶-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1	2005
Professor Alan Calvert Professor Ruth Plummer	The effect of erlotinib on CYP3A4 activity, as quantified by the erythromycin breath test and oral midazolam kinetics in cancer patients: Preliminary results.	2005
Professor Ruth Plummer Dr Andrew Hughes Dr Martin Highley Dr Sathyarathna Gokul Professor Alan Calvert et al.	A phase I trial of ZD9331, a water-soluble, nonpolyglutamatable, thymidylate synthase inhibitor	2003
Professor Ruth Plummer Dr Mark Verrill	Phase I and pharmacokinetic study of BMS-247550 in combination with carboplatin in patients with advanced malignancies	2002
Professor Ruth Plummer Dr Paula Calvert Professor Alan Calvert	Phase I and pharmacokinetic study of the new taxane analog BMS-184476 given weekly in patients with advanced malignancies	2002
Dr Andrew Hughes Dr Paula Calvert Dr Ashraf Azzabi Professor Ruth Plummer Melanie Griffin et al.	Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma	2002
Dr Andrew Hughes Dr Ashraf Azzabi Professor Ruth Plummer Dr Jane Margetts Kevin Fishwick et al.	A phase I dose escalation study of doxorubicin in combination with pemetrexed (Alimta (R), multitargeted antifolate).	2001
Professor Alan Boddy Melanie Griffin Julieann Sludden Huw Thomas Kevin Fishwick et al.	Pharmacological study of paclitaxel duration of infusion combined with GFR-based carboplatin in the treatment of ovarian cancer	2001
Dr Paula Calvert Dr Ashraf Azzabi Dr Andrew Hughes Professor Ruth Plummer Angela Robinson et al.	A phase I clinical and pharmacokinetic study of EPO906 (epothilone B) in patients with advanced solid tumours.	2000
Professor Alan Boddy Melanie Griffin Julieann Sludden Huw Thomas Kevin Fishwick et al.	Paclitaxel and carboplatin dose-intensity and duration of infusion in the treatment of ovarian cancer	2000
Dr Martin Highley Professor Ruth Plummer	Phase I study of BMS-184476, a new taxane analog, given weekly in patients with advanced malignancies	1999
Professor Ruth Plummer Professor Alan Calvert Dr Martin Highley	Phase I trial of ZD9331 in adult patients with refractory solid malignancies administered by 30-min infusion on days 1 and 8 with the cycle repeated every 3 weeks	1999